In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic 'gray zone' of total PSA 4 to 10 ng/mL

Urology

Volumn 52, Issue 3, 1998, Pages 360-365

  Kwiatkowski, Maciej K ^b   Recker, Franz ^a   Piironen, Timo ^b   Pettersson, Kim ^b   Otto, Thomas ^b   Wernli, Martin ^b   Tscholl, Reto ^b  

^a Clinic of Urology   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

KALLIKREIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; HUMAN; KALLIKREIN KININ SYSTEM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN DETERMINATION;

AGED; AGED, 80 AND OVER; DIAGNOSIS, DIFFERENTIAL; HUMANS; KALLIKREINS; MALE; MIDDLE AGED; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS;

EID: 17744400811     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00245-3     Document Type: Article

References (23)

1. 1. Stamey TA, Yang N, Hay AR, et al: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317: 909-916, 1987.
2. 2. Catalona WJ, Richie JP, Ahmann FR, et al: Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 151: 1283-1290, 1994.
3. 3. Carter HB, Pearson JD, Metter EJ, et al: Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. J Am Med Assoc 267: 2215-2220, 1992.
4. 4. Benson MC, Whang IS, Olsson CA, et al: The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 147: 817-821, 1992.
5. 5. Oesterling JE, Jacobsen SJ, Klee GG, et al: Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol 154: 1090-1095, 1995.
6. 6. Christensson A, Bjork T, Nilsson O, et al: Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol 150: 100-105, 1993.
7. 7. Bangma CH, Rietbergen JB, Kranse R, et al: The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population. J Urol 157: 2191-2196, 1997.
8. 8. McCormack RT, Rittenhouse HG, Finlay JA, et al: Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. Urology 45: 729-744, 1995.
9. 9. Henttu P, and Vihko P: cDNA coding for the entire human prostate specific antigen shows high homologies to the human tissue kallikrein genes. Biochem Biophys Res Commun 160: 903-910, 1989.
10. 10. Young CY, Andrews PE, Montgomery BT, et al: Tissue-specific and hormonal regulation of human prostate-specific glandular kallikrein. Biochemistry 31: 818-824, 1992.
11. 11. Clements JA: The glandular kallikrein family of enzymes: tissue-specific expression and hormonal regulation. Endocr Rev 10: 393-419, 1989.
12. 12. Chapdelaine P, Paradis G, Tremblay RR, et al: High level of expression in the prostate of a human glandular kallikrein mRNA related to prostate-specific antigen. FEBS Lett 236: 205-208, 1988.
13. 13. Henttu P, Lukkarinen O, and Vihko P: Expression of the gene coding for human prostate-specific antigen and related hGK-1 in benign and malignant tumors of the human prostate. Int J Cancer 45: 654-660, 1990.
14. 14. Darson MF, Pacelli A, Roche P, et al: Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. Urology 49: 857-862, 1997.
15. 15. Diamandis EP, and Yu H: Nonprostatic sources of prostate-specific antigen. Urol Clin North Am 24: 275-282, 1997.
16. 16. Lovgren J, Rajakoski K, Karp M, et al: Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. Biochem Biophys Res Commun 238: 549-555, 1997.
17. 17. Christensson A, Laurell CB, and Lilja H: Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 194: 755-763, 1990.
18. 18. Piironen T, Lovgren J, Karp M, et al: Immunofluorometric assay for sensitive and specific measurement of human prostatic glandular kallikrein (hK2) in serum. Clin Chem 42: 1034-1041, 1996.
19. 19. Mitrunen K, Pettersson K, Piironen T, et al: Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum. Clin Chem 41: 1115-1120, 1995.
20. 20. Pettersson K, Piironen T, Seppala M, et al: Free and complexed prostate-specific antigen (PSA): in vitro stability, epitope map, and development of immunofluorometric assays for specific and sensitive detection of free PSA and PSA-alpha 1-antichymotrypsin complex. Clin Chem 41: 1480-1488, 1995.
21. 21. Hanley JA, and McNeil BJ: The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143: 29-36, 1982.
22. 22. Becker C, Piironen T, Pettersson K, et al: Clinical utility of a novel, highly sensitive and specific assay for human prostatic glandular kallikrein (hK2) in serum. J Urol 157(suppl): 441, 1997.
23. 23. Semjonow A, Oberpenning F, Brandt B, et al: Impact of free prostate-specific antigen on discordant measurement results of assays for total prostate-specific antigen. Urology 48(suppl): 10-15, 1996.